The purpose of the 2017 EMCDDA TDI/treatment expert meeting is to facilitate the exchange among European experts on the latest developments of drug treatment monitoring in Europe.
The specific objectives of this year's meeting are to present current national achievements and progress in monitoring drug treatment demands and treatment provision, to provide an update on specific on-going projects, to discuss data quality, analysis and interpretation, and to discuss on how treatment related data can inform policy and responses to new drug trends.
A particular focus of this year’s two-days meeting is data quality and analysis. The need to adapt the current data collection to an evolving drug and socio-demographic reality will be explored. A specific space will be dedicated to the interpretation of trends in TDI and other treatment data, discussing with the national experts what issues should be considered when analysing temporal trends and how consistencies and inconsistencies of the indicators in analysing trends can be interpreted. These issues will be discussed in plenary and parallel sessions on Wednesday and Thursday.
On Wednesday 20 September, two joint sessions with DRD experts will take place in the morning. One session will focus on ageing among high–risk drug users in and out of treatment. The other session will explore the implications for policy, responses and monitoring, and the use of treatment–related data for conducting mortality cohort studies.
The last session of the TDI meeting (Thursday 21 September in the afternoon) will focus on the use of treatment–related data to inform responses, psychiatric comorbidity, the relation between referral sources and clients’ patterns of drug use. The main outlines of the upcoming European guide to health and social responses to drug use will be presented.
The main findings from the meeting will be disseminated among our national experts, the wider Reitox network and all stakeholders interested in treatment-related data. This document should serve as a reference point for our network of treatment experts.